Molecular Analysis for Therapy Choice (MATCH)
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / email@example.com
To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas (including breast cancer, esophageal cancer, lung cancer, sarcomas - bone and soft tissue), thyroid cancer, cervical cancer, ovarian cancer, Hodgkin's disease, non-Hodgkin's lymphoma, pancreatic cancer, colon and rectal cancer, head and neck cancers, skin cancers, melanoma, prostate cancer, and testicular cancer).
This study is closed
Richard Carvajal, MD
|Are you 18 years of age or older?
|Do you have advanced refractory cancer/lymphoma? (listed in summary)